Americans appreciate their vaccine makers. Cases in point? Moderna and Pfizer leapfrogged into the top 10 favorite companies in the U.S. in the yearly Axios Harris 100 survey.
They are the first Biopharma firms to make it to the top 10 in the ranking’s 20-year history. Johnson & Johnson which lists pharma as one of its three divisions, has made it to the top 10 before; this year, it was No. 72 on the list with a reputation score approximately the same as 2020’s.
Meanwhile, Moderna ranked third, while Pfizer was Number 7 on the strength of its product and innovation scores, recording high marks for vision and culture along the way.
“That’s not typical at all and reinforces that it is not just a product, it’s that people are seeing these companies in a very different light,” The Harris Poll Managing Director Rob Jekielek disclosed. “They get that there’s a vaccine, but they also see the incredible leadership drive, and they clearly see the people behind the vaccines – the scientists.”
Both Pfizer and Moderna recorded 10 to 20 points higher across all metrics when compared to last year’s results. Pfizer rose 54 places in the rank, while Moderna did not make the 2020 top 100 at all.
Still more exceptional, particularly for previously unknown Moderna, is that Harris draws its list of top 100 companies from write-in votes. This means, they ask over 40,000 people to name companies offhand versus giving a predetermined list to choose from. Researchers then make use of the information to draw the list of the 100 most popular companies.
A second survey asks people if they are “familiar or very familiar” with a specific company. Those who say yes proceed to answer questions about the company. Harris calculates a final reputation score for each company by measuring culture, trust, ethics, vision, growth, citizenship, product and services based on innovation and quality.